HAMBURG, Germany, Sept. 18, 2008 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT.F - News) (NasdaqGM:EVTC - News) today announced that Jorn Aldag, President & CEO and Dr John Kemp, Chief Research & Development Officer will present at the UBS Global Life Sciences Conference in New York.

 Date: Wednesday, September 24, 2008
 Time: 10.30 am EDT (04.30 pm CEST/03.30 pm BST)
 Venue: Grand Hyatt, New York City, US

A live webcast of the presentation will be accessible through the Evotec website at http://www.evotec.com - Investors. A replay will be available at http://www.evotec.com - Investors - Webcasts.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programs and through research collaborations, it is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries. In proprietary projects, Evotec specializes in finding new treatments for diseases of the Central Nervous System. Evotec has three programs in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation. Evotec's proprietary preclinical research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Evotec has worldwide license agreements with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1) antagonists. For additional information please go to http://www.evotec.com

          Evotec AG
          Anne Hennecke, SVP, Investor Relations 
           & Corporate Communications
          +49.(0)40.56081-286
          Fax: +49.(0)40.56081-333
          anne.hennecke@evotec.com